Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
162
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Old Age is an Independent Risk Factor for Pneumonia Development in Patients with SARS-CoV-2 Omicron Variant Infection and a History of Inactivated Vaccine Injection

Xuecheng Tong1 Institute of Hepatology, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of China;2 Department of Infectious Diseases, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of ChinaView further author information
,
Zeyu Huang1 Institute of Hepatology, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of ChinaView further author information
,
Xiujun Zhang1 Institute of Hepatology, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of China;2 Department of Infectious Diseases, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of ChinaView further author information
,
Guocan Si2 Department of Infectious Diseases, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of ChinaView further author information
,
Huifen Lu2 Department of Infectious Diseases, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of ChinaView further author information
,
Wei Zhang2 Department of Infectious Diseases, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of ChinaView further author information
,
Yuan Xue1 Institute of Hepatology, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of China;2 Department of Infectious Diseases, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-5428-0058View further author information
ORCID Icon &
Weibin Xie3 Department of Anesthesiology, the Third People’s Hospital of Changzhou, Changzhou, People’s Republic of ChinaView further author information
 show all
Pages 5567-5573 | Received 25 Jun 2022, Accepted 15 Sep 2022, Published online: 21 Sep 2022

References

  • Ai J, Wang X, He X, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30(8):1077–1083.e4. doi:10.1016/j.chom.2022.05.001
  • Yu X, Wei D, Xu W, et al. Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination. Cell Discov. 2022;8(1):4. doi:10.1038/s41421-022-00375-5
  • Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet. 2022;399(10340):2011–2012. doi:10.1016/S0140-6736(22)00838-8
  • Chavda VP, Hanuma Kumar Ghali EN, Yallapu MM, Apostolopoulos V. Therapeutics to tackle Omicron outbreak. Immunotherapy. 2022;14(11):833–838. doi:10.2217/imt-2022-0064
  • YA E-M YM, Saleh AK, Saleh AK, et al. A comprehensive insight into current control of COVID-19: immunogenicity, vaccination, and treatment. Biomed Pharmacother. 2022;153:113499. doi:10.1016/j.biopha.2022.113499
  • Fan Y, Li X, Zhang L, et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141. doi:10.1038/s41392-022-00997-x
  • Harrigan SP, Wilton J, Chong M, et al. Clinical severity of Omicron SARS-CoV-2 variant relative to Delta in British Columbia, Canada: a retrospective analysis of whole genome sequenced cases. Clin Infect Dis. 2022. doi:10.1093/cid/ciac705
  • Ito N, Kitahara Y, Miwata K, Okimoto M, Takafuta T. Comparison of COVID-19 pneumonia during the SARS-CoV-2 Omicron wave and the previous non-Omicron wave in a single facility. Respir Investig. 2022. doi:10.1016/j.resinv.2022.08.001
  • Kinikar AA, Vartak S, Dawre R, et al. Clinical profile and outcome of hospitalized confirmed cases of omicron variant of SARS-CoV-2 among children in Pune, India. Cureus. 2022;14(4):e24629. doi:10.7759/cureus.24629
  • Murillo-Zamora E, Trujillo X, Huerta M, et al. First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence. Public Health. 2022;207:105–107. doi:10.1016/j.puhe.2022.04.001
  • Ito N, Kitahara Y, Miwata K, Okimoto M, Takafuta T. Can the Omicron variant of COVID-19 cause pneumonia in young patients without risk factors? Clin Case Rep. 2022;10(5):e05684. doi:10.1002/ccr3.5684
  • Hoffmann M, Kruger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456e411. doi:10.1016/j.cell.2021.12.032
  • Li M, Liu Q, Wu D, et al. Association of COVID-19 vaccination and clinical severity of patients infected with delta or Omicron variants - China, May 21, 2021-February 28, 2022. China CDC Wkly. 2022;4(14):293–297. doi:10.46234/ccdcw2022.074
  • China NHCotPsRo. Diagnosis and treatment plan for COVID-19(trial version 9). Int J Epidemiol Infect Dis. 2;2022. doi:10.3760/cma.j.cn331340-20220325-00065
  • Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604(7906):553–556. doi:10.1038/s41586-022-04594-4
  • Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–675. doi:10.1038/s41586-021-04389-z
  • Wang K, Jia Z, Bao L, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022;603(7903):919–925. doi:10.1038/s41586-022-04466-x
  • Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2022;116:38–42. doi:10.1016/j.ijid.2021.12.357
  • Long H, Li J, Li R, et al. Plasma glucose levels and diabetes are independent predictors for mortality in patients with COVID-19. Epidemiol Infect. 2022;150:e106. doi:10.1017/S095026882200022X
  • Vargas-Rodriguez JR, Valdes Aguayo JJ, Garza-Veloz I, et al. Sustained hyperglycemia and its relationship with the outcome of hospitalized patients with severe COVID-19: potential role of ACE2 upregulation. J Pers Med. 2022;12(5):805. doi:10.3390/jpm12050805
  • Yang P, Wang N, Wang J, et al. Admission fasting plasma glucose is an independent risk factor for 28-day mortality in patients with COVID-19. J Med Virol. 2021;93(4):2168–2176. doi:10.1002/jmv.26608
  • Zhao Y, Xing H, Xu Y. Influence of fasting plasma glucose level on admission of COVID-19 patients: a retrospective study. J Diabetes Res. 2022;2022:7424748. doi:10.1155/2022/7424748
  • Chen B, Lu C, Gu HQ, et al. Serum uric acid concentrations and risk of adverse outcomes in patients with COVID-19. Front Endocrinol. 2021;12:633767. doi:10.3389/fendo.2021.633767
  • Hu F, Guo Y, Lin J, et al. Association of serum uric acid levels with COVID-19 severity. BMC Endocr Disord. 2021;21(1):97. doi:10.1186/s12902-021-00745-2

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.